BioSpace News Archive

Pacific Biosciences of California, Inc. announced today the companies have closed the transaction under which Pacific Biosciences acquired Omniome.

Femasys Inc., a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies, announced that the Company has been added to the Russell Microcap® Index when the U.S. market opened.

Conformis, Inc. (NASDAQ:CFMS) provided today an update of its third quarter revenue performance expectations in advance of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (“OpCo Summit”).

Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Annie Drapeau and Teri Loxam to its board of directors.

Amedisys, Inc., (NASDAQ: AMED), a leading provider of quality home health, hospice and personal care, has signed a definitive agreement to acquire regulatory assets that allow the Company to establish home health care centers to fully service and expand the Charlotte and Raleigh, N.C. markets.

Seagen Inc. and Genmab A/S announced that the U.S. Food and Drug Administration has granted accelerated approval to TIVDAK™, the first and only approved antibody-drug conjugate for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Telix Pharmaceuticals Limited has welcomed the Society of Nuclear Medicine and Molecular Imaging updated Appropriate Use Criteria for prostate specific membrane antigen positron emission tomography imaging.

The Company held a Special Meeting to approve a Name Change as the Company’s core competencies and product offerings have organically grown beyond the medical device industry, and this expansion into new industries and businesses will be reflected in the Name Change.

A OneLegacy Foundation funded clinical trial at UCLA Health announced today its first two successful kidney transplants with the potential for no immunosuppressive drugs, a feat that will open the door for safer, more effective organ transplants for the more than 107,000 Americans in need.

USA News Group - Oncology data leader COTA recently released a recent survey where half of the respondents pointed to “Operation Warp Speed” as evidence that cancer treatments can and should be moving forward faster.